363
Views
60
CrossRef citations to date
0
Altmetric
Short Report

Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control

, , , , &
Pages 213-217 | Published online: 17 Jul 2012

Abstract

Background

Suboptimal glycemic control is a common situation in diabetes, regardless of the wide range of drugs available to reach glycemic targets. Basic research in diabetes is endeavoring to identify new actives working as insulin savers, use of which could delay the introduction of injectable insulin or reduce the insulin dose needed. Commonly available as a nutraceutical, berberine is a potential candidate.

Methods and results

Because its low oral bioavailability can be overcome by P-glycoprotein inhibitors like herbal polyphenols, we have tested the nutraceutical combination of Berberis aristata extract and Silybum marianum extract (Berberol®) in type 2 diabetes in terms of its additive effect when combined with a conventional oral regimen for patients with suboptimal glycemic control. After 90 days of treatment, the nutraceutical association had a positive effect on glycemic and lipid parameters, significantly reducing glycosylated hemoglobin, basal insulin, homeostatic model assessment of insulin resistance, total and low-density lipoprotein cholesterol, and triglycerides. A relevant effect was also observed in terms of liver function by measuring aspartate transaminase and alanine transaminase. The product had a good safety profile, with distinctive gastrointestinal side effects likely due to its acarbose-like action.

Conclusion

Although further studies should be carried out to confirm our data, Berberol could be considered a good candidate as an adjunctive treatment option in diabetes, especially in patients with suboptimal glycemic control.

Introduction

Diabetes mellitus is recognized as a group of heterogeneous disorders, with common elements of hyperglycemia and glucose intolerance due to insulin deficiency, impaired effectiveness of insulin action, or both. The prevalence of type 2 diabetes increases with age, is increasing worldwide, and its economic impact currently accounts for a significant portion of health care expenditure.Citation1 Injection of long-acting insulin is a common therapeutic approach for patients with type 2 diabetes that is poorly controlled with multiple oral regimens.Citation2 Unfortunately, although insulin use as the mainstay of treatment for diabetes has resulted in favorable treatment outcomes, poor adherence/compliance continues to be a problem because of fear of insulin or fear of injection, and this can be associated with poor glycemic control, clinical complications, psychological comorbidity, poor general well being and health status, and increased mortality risk in patients with diabetes.Citation3 Last but not least, use of insulin is very often considered to be the “point of no return” in medical intervention for diabetes. These observations suggest a need for implementation of new therapeutic strategies to delay the need for insulin as far as possible.

Berberine, an isoquinoline alkaloid of the protoberberine type and found in an array of plants, has been used in Indian and Chinese medicine for many decades. It is present in Hydrastis canadensis (goldenseal), Coptis chinensis (Coptis or goldenthread), Berberis aquifolium (the Oregon grape), Berberis vulgaris (barberry), and Berberis aristata (tree turmeric). Berberine and extracts of berberine have demonstrated significant antimicrobial activity against a variety of organisms, including bacteria, viruses, fungi, protozoans, helminths, and chlamydia. The predominant clinical uses of berberine, at least in the recent past, have included bacterial diarrhea and intestinal parasite infections.Citation4

More recently, clinical research on berberine has revealed novel pharmacological properties and multiple therapeutic applications, mainly concerning hypercholesterolemia and diabetes.Citation5 With regard to the lipid profile, berberine upregulates low-density lipoprotein receptor expression independent of sterol regulatory element-binding proteins, but dependent on extracellular signal-regulated kinases and c-Jun N-terminal kinase activation, leading to reductions in total cholesterol and low-density lipoprotein cholesterol of about 30% and 25%, respectively. This upmodulation occurs via a post-transcriptional mechanism that stabilizes mRNA and enables berberine to act as a cholesterol-lowering drug via a mechanism of action different from that of the statins.Citation6 In addition to its cholesterol-lowering properties, berberine reduces triglycerides by about 35%. These effects on the lipid profile have been observed in both animals and humans.Citation6,Citation7

Berberine also has an important additive effect in the presence of statins.Citation8 This is likely due to the ability of berberine to downmodulate proprotein convertase subtilisin/kexin type 9, a protein which reduces the cholesterol-lowering properties of statins.Citation9 This effect of berberine could be relevant when treating patients with suboptimal control of hypercholesterolemia despite receiving high doses of statins. Due to this additive effect, it is quite common to find nutritional supplements containing berberineCitation10 along with a natural source of lovastatin (ie, Monascus purpureus).Citation11 However, these products do not take into consideration the poor standardization of the raw materialsCitation12 and the risk to consumers due to the possible presence of mycotoxic contaminants like citrinin.Citation13

Berberine has also been shown to be effective in the treatment of diabetes, in which it significantly decreases glycosylated hemoglobin (HbA1c), fasting blood glucose, and postprandial blood glucose. In this respect, berberine has an effect similar to that of metformin,Citation14 even if it likely acts via a mechanism different from that of metformin.Citation15

Berberine regulates glucose metabolism via multiple mechanisms of action. It enhances glucose uptake by upmodulation of glucose transporter type 4, activates 5′-AMP-activated protein kinase as a consequence of inhibition of mitochondrial function, suppresses adipogenesis by inhibition of peroxisome proliferator-activated receptor gamma and C-enhancer-binding protein alpha function, and decreases intestinal glucose absorption by inhibition of alpha-glucosidase. Citation16 However, despite these functions, berberine has poor oral bioavailability.Citation17 In humans, this appears to be due to a P-glycoprotein-mediated gut extrusion processCitation18 and substantial excretion in bile.Citation19 P-glycoprotein seems to decrease the amount of berberine able to cross enterocytes by about 90%,Citation20 suggesting that inhibition of P-glycoprotein could potentially improve its oral poor bioavailability. Among the potential P-glycoprotein inhibitors, silymarin from Silybum marianum could be a good candidate due to its very poor oral bioavailability and its good safety profile.Citation21

Therefore, we investigated the activity of a combination of berberine and silymarin when added to oral hypoglycemic regimens for patients with suboptimal glycemic control. Our aim was to evaluate the impact of this approach on body mass index, hyperglycemia, hypercholesterolemia, triglyceride levels, and liver enzymes in patients with type 2 diabetes.

Materials and methods

The study was performed in routine clinical practice in accordance with international guidelines and in line with the principles outlined in the Declaration of Helsinki, so approval from the local ethics board was not required. This study was carried out in a single center in Italy where it is not mandatory to obtain ethical approval when performing experiments involving nutraceutical products. Twenty-six patients diagnosed with type 2 diabetes were enrolled. The patient demographics are shown in . Twenty-two of the 26 patients completed the study, with four dropouts as a result of gastrointestinal discomfort and/or other side effects.

Table 1 Demographic characteristics of the 22 patients who completed the study

The main inclusion criteria were stable (for at least 6 months) but suboptimal glycemic control (HbA1c 7.5%–9.5%), body mass index > 22 kg/m2, age 25–75 years, and a negative pregnancy test for female patients. All patients had suboptimal glycemic control despite use of the following drugs, unchanged at least in the last 3 months: metformin (n = 20), incretins (n = 4), sulfonylureas (n = 14), glitazones (n = 3), and insulin (n = 5). Twenty patients were also receiving antihypertensive drugs, and 13 were receiving anticoagulant therapy. As regards the lipid profile, 12 patients were receiving statins, 1 was receiving a fibrate whereas 5, previously under treatment with statins, had interrupted the therapy due to unwanted effects, mainly myalgia.

Exclusion criteria were moderate to severe liver dysfunction (serum alanine aminotransferase > 120 IU/L and aspartate aminotransferase > 80 IU/L), abnormal renal function (serum creatinine > 115 μmol/L), severe heart failure (New York Heart Association Class III or greater), history of acute diabetic complications, including diabetic ketoacidosis or hyperosmolar hyperglycemic nonketotic coma, psychiatric disease, severe infection, pregnancy or planning for pregnancy, and fasting plasma glucose ≥ 200 mg/dL.

All patients received addon nutraceutical therapy, ie, Berberol® (PharmExtracta, Pontenure, Italy), an oral tablet containing 588 mg of B. aristata extract titered as 85% berberine and 105 mg of S. marianum extract titered as >60% flavonolignans. The product, in agreement with the Italian legislation (law number 169/2004) had been notified to the Minister of Health in 2010 (E10 40753Y) and registered as a food supplement, with both its actives (standardized extracts of B. aristata and S. marianum) belonging to the list of botanicals approved as nutraceuticals and its excipients all being food grade. The patients took two tablets per day on an empty stomach in the late evening for the 90-day duration of the study. Berberol was manufactured by SIIT (Trezzano S/N, Milan, Italy). The two actives, ie, B. aristata extract and S. marianum extract, were provided, respectively, by SIIT and Indena, both located in Milano, Italy.

Statistical analysis

The statistical analysis was performed using SPSS 12.0 for Windows (SPSS Inc, Chicago, IL). Statistical differences between baseline and different time points were analyzed using the nonparametric paired t-test. The α level was set at 0.05.

Results

Berberol containing extracts of B. aristata and S. marianum extract, dosed at two tablets daily for 90 days, was demonstrated to be a valid addon treatment option for patients with type 2 diabetes and suboptimal glycemic control. As shown in , a significant reduction was observed in HbA1c, basal insulin, total cholesterol, low-density lipoprotein cholesterol, triglycerides, HOMA-R (homeostatic model assessment for insulin resistance, calculated as glucose × insulin/405, where glucose is expressed as mg/dL and insulin as μU/mL), and alanine transaminase. Aspartate transaminase also showed a downwards trend. There were no significant changes in high-density lipoprotein cholesterol, fasting glucose, body mass index, weight, or waist circumference.

Table 2 Effect of adjunctive Berberol therapy after 90 days of treatment in 22 patients with type 2 diabetes and suboptimal glycemic control

Discussion

Four of the 26 patients diagnosed with type 2 diabetes and suboptimal glycemic control who enrolled in this study dropped out, leaving data for the 22 patients who completed the study. We investigated the clinical effects of oral treatment using a nutraceutical combination of B. aristata extract (containing 85% berberine) and S. marianum extract. The latter ingredient is included with the aim of enhancing the oral bioavailability of berberine, mostly by reducing P-glycoprotein activity in the gut. To be eligible for entry into this study, patients had to have had suboptimal glycemic control (HbA1c 7.5%–9.5%) unchanged for at least 3 months despite at least 6 months of treatment with a multidrug regimen. According to the international guidelines, HbA1c values in this range are linked with an increased risk of developing microvascular and macrovascular complications, and all possible medical effort should be made to reduce HbA1c below 7%.Citation22 Use of injectable insulin should be delayed as long as possible using oral insulin-saving drug cocktails. The basis for using such cocktails, precisely established on the basis of the metabolic features of a patient, have to be considered carefully, not only because of the very poor patient compliance with insulin injections, but also because delaying insulin therapy should spare endogenous insulin and avoid pancreatic exhaustion.Citation23

In patients with suboptimal glycemic control, we observed an HbA1c reduction of about 0.85% after 3 months of treatment with Berberol, which was maintained after 6 months of treatment (data not shown). Such a percentage reduction is comparable with that normally obtained in patients treated with acarbose, dipeptidyl peptidase-4 inhibitors (sitagliptin, vildagliptin, saxagliptin), or glitazones, used alone or adjunctive to metformin, to achieve optimal glycemic control.

We did not modify any drug or treatment protocol established before starting treatment with Berberol in any of the 22 patients who completed the study. At the same time, no modifications in terms of food intake or lifestyle were suggested or adopted before or during the trial, and this is reflected by the minimal changes in body weight and waist circumference.

A possible mechanism of action of Berberol could be its ability to increase insulin sensitivity, as shown by the reduction in HOMA-R. Another possible mechanism of action could be linked to the acarbose-like action observed by some clinicians.Citation24 This hypothesis should explain some of the gastrointestinal side effects observed, and could explain why four patients dropped out of the trial.

We observed a relevant reduction in total cholesterol, low-density lipoprotein cholesterol, and triglycerides in our patients, all of whom had a cholesterol value within normal range or were on treatment with statins. This result, already observed by many clinicians, is likely due to the hypocholesterolemic activity of berberine and to an additive effect of berberine when combined with statin therapy.

Another effect was the reduction in alanine and aspartate transaminase levels. Similar observations have been made in animals and in humans, and berberine has been shown to reduce liver necrosis both in nonalcoholic steatosis and in steatosis due to hepatitis C infection.Citation25 However, these observations need to be confirmed by studies specifically designed to demonstrate a protective effect of berberine on the liver.

Conclusion

Berberol is a nutraceutical combination of highly standardized herbal extracts of B. aristata and S. marianum titered, respectively, as 85% berberine and >60% flavanolignans. Berberol seems to have positive effects in patients with type 2 diabetes and suboptimal glycemic control when given orally in addition to a conventional regimen (ie, metformin, dipeptidyl peptidase-4 inhibitors, glitazones, acarbose or insulin, alone or as multidrug therapy). Berberol seems to improve the cholesterol-lowering properties of statins, and has a positive effect on liver enzymes. Treatment seems to be safe and tolerated at the doses tested, with minimal unwanted effects, which resolve on cessation of treatment without any further consequences. The results of our pilot study performed in 26 patients need confirmation by larger trials and with better definition of the diabetic patients enrolled. Allowing for these limitations, Berberol can still be considered as a potential oral nutraceutical suitable for use in addition to conventional therapy for type 2 diabetes, with the aim of ameliorating suboptimal glycemic control as a strategy for postponing the use of injectable insulin.

Disclosure

FDP developed and has patented the Berberol used in this study.

References

  • Shamseddeen H Getty JZ Hamdallah IN Ali MR Epidemiology and economic impact of obesity and type 2 diabetes Surg Clin North Am 2011 91 6 1163 1172 vii 22054146
  • Donner T Munoz M Update on insulin therapy for type 2 diabetes J Clin Endocrinol Metab 3 22 2012
  • Fu AZ Qiu Y Radican L Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes Curr Med Res Opin 2009 25 6 1413 1420 19422281
  • [No authors listed] Berberine Altern Med Rev 2000 5 2 175 177 10767672
  • Vuddanda PR Chakraborty S Singh S Berberine: a potential phytochemical with multispectrum therapeutic activities Expert Opin Investig Drugs 2010 19 10 1297 1307
  • Kong W Wei J Abidi P Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins Nat Med 2004 10 12 1344 1351 15531889
  • Hu Y Davies GE Berberine inhibits adipogenesis in high-fat diet-induced obesity mice Fitoterapia 2010 81 5 358 366 19861153
  • Kong WJ Wei J Zuo ZY Combination of simvastatin with berberine improves the lipid-lowering efficacy Metabolism 2008 57 8 1029 1037 18640378
  • Cameron J Ranheim T Kulseth MA Leren TP Berge KE Berberine decreases PCSK9 expression in HepG2 cells Atherosclerosis 2008 201 2 266 273 18355829
  • Affuso F Ruvolo A Micillo F Saccà L Fazio S Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study Nutr Metab Cardiovasc Dis 2010 20 9 656 661 19699071
  • Klimek M Wang S Ogunkanmi A Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia P T 2009 34 6 313 327 19572049
  • Gordon RY Cooperman T Obermeyer W Becker DJ Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 2010 170 19 1722 1727 20975018
  • Lin YL Wang TH Lee MH Su NW Biologically active components and nutraceuticals in the Monascus-fermented rice: a review Appl Microbiol Biotechnol 2008 77 5 965 973 18038131
  • Yin J Xing H Ye J Efficacy of berberine in patients with type 2 diabetes mellitus Metabolism 2008 57 5 712 717 18442638
  • Zhang H Wei J Xue R Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression Metabolism 2010 59 2 285 292 19800084
  • Yin J Zhang H Ye J Traditional Chinese medicine in treatment of metabolic syndrome Endocr Metab Immune Disord Drug Targets 2008 8 2 99 111 18537696
  • Chen W Miao YQ Fan DJ Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats AAPS Pharm Sci Tech 2011 12 2 705 711
  • Pan GY Wang GJ Liu XD Fawcett JP Xie YY The involvement of P-glycoprotein in berberine absorption Pharmacol Toxicol 2002 91 4 193 197 12530470
  • Tsai PL Tsai TH Hepatobiliary excretion of berberine Drug Metab Dispos 2004 32 4 405 412 15039293
  • Chae HW Kim IW Jin HE Kim DD Chung SJ Shim CK Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine Arch Pharm Res 2008 31 1 103 110 18277615
  • Zhou S Lim LY Chowbay B Herbal modulation of P-glycoprotein Drug Metab Rev 2004 36 1 57 104 15072439
  • Paquot N Scheen AJ Which HbA1c and lipid targets in patients with type 2 diabetes? Rev Med Liege 2012 67 2 98 103 French 22482240
  • Porte DJr Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications Diabetes Metab Res Rev 2001 17 3 181 188 11424231
  • Liu L Yu YL Yang JS Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study Naunyn Schmiedebergs Arch Pharmacol 2010 381 4 371 381 20229011
  • Zhang BJ Xu D Guo Y Ping J Chen LB Wang H Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors Clin Exp Pharmacol Physiol 2008 35 3 303 309 17973934